Astria Therapeutics Inc. has gained IND clearance from the FDA for STAR-0310, a monoclonal antibody OX40 antagonist being developed for atopic dermatitis. BioWorld Science Regulatory Dermatologic ...

STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in development for the potential treatment of atopic dermatitis (AD) and potentially other ...

Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx ...

Astria Therapeutics (ATXS) announced initiation of a Phase 1a clinical trial of STAR-0310 in healthy subjects. STAR-0310, a high affinity ...

H.C. Wainwright maintained a Buy rating on Astria Therapeutics stock, with a price target of $16.00. The firm's decision follows Astria's announcement of the initiation of a Phase 1a study for ...

The interest around OX40 antagonists in diseases like atopic dermatitis comes despite disappointing clinical results with OX40 agonist drugs in oncology in development at companies like ...

Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx ...